NEW YORK, Feb. 7 - Nanogen and Gentris, a clinical pharmacogenomics testing and diagnostics company, have partnered to study drug-metabolizing enzymes and transporter markers, the firms said jointly on Thursday.
Terms of the open-ended deal call for Nanogen to provide its NanoChip molecular biology workstation to Gentris, which will use it to develop certain SNP assays.
Gentris brings to the table its "experience in clinical application methodology to be able to apply it to [Nanogen's] platform," a Gentris spokeswoman said.
Nanogen will have exclusive rights to commercialize any assays that are developed and will shell out "certain payments" to Gentris if it happens to sell the assays after receiving approval from the US Food and Drug Administration, the companies said.
Further financial details of the agreement were not disclosed.
Nanogen hope that the deal will help it "develop and commercialize ... new tests ... and allow us to enter the clinical pharmacogenomic market," Randy White, Nanogen's CEO, said in a statement.
In November last year, Gentris partnered with MDS Pharma Services to establish a genomic database of genotyped volunteers and diagnostic reference controls.
Terms of that agreement call for Gentris to genotype individuals for genes associated with drug metabolism for MDS' gene library. In return, Gentris will gain access to the library, whose samples "will be immediately commercialized" by Gentris and an undisclosed number of collaborators as pharmacogenomic diagnostics.